Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of AD-209
Condition or disease : hypertension Intervention/treatment Drug : AD-209 Drug : AD-209-1A Drug : AD-209-1B Drug : AD-209-1C Drug : AD-209 Placebo Drug : AD-209-1 Placebo Phase : Phase 2
Age
19 - 74 years
Sex
ALL
Healthy Volunteers
No
Korea University Guro Hospital
Seoul, South Korea
Start Date
April 5, 2023
Primary Completion Date
November 27, 2023
Completion Date
November 27, 2023
Last Updated
April 5, 2024
221
ACTUAL participants
AD-209
DRUG
AD-209-1A
DRUG
AD-209-1B
DRUG
AD-209-1C
DRUG
AD-209 placebo
DRUG
AD-209-1 placebo
DRUG
Lead Sponsor
Addpharma Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions